Q-omics provides the consensus-scored CR2 profile across patient tissues and cancer cell-line models. CR2 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, CR2 is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CR2 RNA expression shows 13,398 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, KIRC, and LSCC as cancer lineages where CR2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CR2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CR2 survival associations across molecular data types. CR2 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CR2 RNA expression–survival associations across cancer types. High CR2 expression shows unfavorable associations in UVM, but favorable associations in HNSC, SKCM, LUAD, BRCA and ACC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for CR2 RNA expression.
This table summarizes CR2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for CR2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CR2 shows lower tumor expression in KIRC, KIRP and COAD and higher tumor expression in LUAD, CHOL and STAD. The KIRC box plot shows higher CR2 RNA expression in normal versus tumor tissue (log2 FC = −1.825, t-test p < 0.001).
This table shows molecular features associated with CR2 in patient tissues and cancer cell lines. In patient samples, CR2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CR2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in URINARY_TRACT and LARGE_INTESTINE.
